Research Topics
| H SilverSummaryAffiliation: Technion-Israel Institute of Technology Country: Israel Publications
| Collaborators
|
Detail Information
Publications
SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patientsHenry Silver
Molecular Neuropsychiatry Unit, Sha ar Menashe Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, and Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
Int J Neuropsychopharmacol 14:573-84. 2011..These changes may be part of the mechanism of clinically effective drug action and may prove to be biomarkers of pharmacological response...
The Role of GABA-A Receptor in the Synergism Between SSRI and Antipsychotic in Schizophrenia; Implications for Antipsychotic Modes of ActionsHenry Silver
Brain Behavior Laboratory, Shaar Menashe MHC, Mobile Post Hefer 38814, Israel
Curr Med Chem 20:363-70. 2013..In this paper, we review these studies and propose that modulation of the gamma-aminobutyric acid (GABA)-A receptor and its regulating system is the mechanism by which SSRI antipsychotic synergism exerts its clinical efficacy...
Impairment in associative memory in healthy aging is distinct from that in other types of episodic memoryHenry Silver
Sha ar Menashe Mental Health Center, Mobile Post Hefer, Israel
Psychiatry Res 197:135-9. 2012..NAL may thus serve as a selective marker of complex, hippocampus-based, cognitive functions in studies of normal cognitive aging and of its possible relationship to early dementia...
Schizophrenia patients with a history of severe violence differ from nonviolent schizophrenia patients in perception of emotions but not cognitive functionHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
J Clin Psychiatry 66:300-8. 2005..Impaired processing of emotions may relate to violent behavior in schizophrenia patients. We compared emotional function in schizophrenia patients with and without a history of severe violent behavior...
Blood DHEAS concentrations correlate with cognitive function in chronic schizophrenia patients: a pilot studyHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
J Psychiatr Res 39:569-75. 2005..The relationship was independent of the age related reduction in DHEAS levels. These preliminary results suggest that DHEAS may be associated with cognitive impairment in schizophrenia...
Evidence for sustained attention and working memory in schizophrenia sharing a common mechanismHenry Silver
Sha ar Menashe Mental Health Center, and Director, Brain Behavior Laboratory, Mobile Post Hefer 38814, Israel
J Neuropsychiatry Clin Neurosci 17:391-8. 2005....
A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patientsHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Hadera, Israel
Int Clin Psychopharmacol 20:319-26. 2005..Further studies of amantadine with different doses and treatment duration, as well as more glutamate selective agents such as memantine, are indicated...
Impaired error monitoring contributes to face recognition deficit in schizophrenia patientsHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Hadera, Israel
Schizophr Res 85:151-61. 2006..It has been proposed that social and cognitive deficits in schizophrenia may result from impaired error monitoring...
Impairment in error monitoring predicts poor executive function in schizophrenia patientsHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer, Israel
Schizophr Res 94:156-63. 2007..Impaired ability to detect and correct errors may contribute to poor cognitive and social function in schizophrenia...
Suboptimal processing strategy and working-memory impairments predict abstraction deficit in schizophreniaHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Hadera, Israel
J Clin Exp Neuropsychol 29:823-30. 2007..The model presented may enable differentiation between impaired and compensating components in schizophrenia patients with an abstraction deficit...
Analysis of cognitive performance in schizophrenia patients and healthy individuals with unsupervised clustering modelsHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
Psychiatry Res 159:167-79. 2008..This preliminary study suggests that appropriate application of data-mining methods may contribute to investigation of cognitive functions...
Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?Henry Silver
Molecular Neuropsychiatry Unit, Brain Behavior Laboratory, Shaar Menashe Mental Health Center, and Technion Faculty of Medicine, Haifa 32000, Israel
Neurotherapeutics 6:86-93. 2009..Although as yet limited in scope, the findings of definable molecular targets for synergistic SSRI-antipsychotic interaction provide new directions to inform future research and provide novel bio-molecular targets for drug development...
Age in high-functioning healthy men is associated with nonlinear decline in some 'executive' functions in late middle ageHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Sha ar Menashe, Israel
Dement Geriatr Cogn Disord 27:292-300. 2009..Age-related cognitive decline might involve selective deterioration of specific brain systems. We studied the relationship between age and cognition by comparing cognitive function of older and younger high functioning men...
Impaired recognition of happy, sad and neutral expressions in schizophrenia is emotion, but not valence, specific and context dependentHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Hadera, Israel Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
Psychiatry Res 169:101-6. 2009..Processing of neutral expressions was context dependent. Emotion impairment in schizophrenia appears to be selective for the emotion domain but not specific emotions. Test context influences how neutral facial expressions are processed...
'Executive' functions and normal aging: selective impairment in conditional exclusion compared to abstraction and inhibitionHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer, Israel
Dement Geriatr Cogn Disord 31:53-62. 2011..Some executive functions may be selectively impaired in normal aging over and above the general cognitive decline...
Brief emotion training improves recognition of facial emotions in chronic schizophrenia. A pilot studyHenry Silver
Brain Behavior Laboratory Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
Psychiatry Res 128:147-54. 2004..This may be due to increased patient awareness of emotional aspects of stimuli and/or improvement in specific emotional perceptual skills. Further studies of Emotion Training as a potential treatment modality are warranted...
Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophreniaHenry Silver
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
Expert Opin Pharmacother 5:2053-8. 2004..A better understanding of these mechanisms can shed light on the pathogenesis of negative symptoms and provide new targets for drug development...
Impaired visuomotor function in schizophrenic patients compared with control subjectsHenry Silver
Flugelman Psychiatric Hospital, Mobile Post Ashrat, Israel
J Neuropsychiatry Clin Neurosci 14:72-6. 2002..The impairments were not related to medication dose or to extrapyramidal side effects. Visuomotor impairment may be part of illness-related pathology in schizophrenia...
Verbal as well as spatial working memory predicts visuospatial processing in male schizophrenia patientsHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
Schizophr Res 101:210-7. 2008..In this study we investigated the relationship among VSP, VWM and SWM...
Perception of facial emotions in chronic schizophrenia does not correlate with negative symptoms but correlates with cognitive and motor dysfunctionH Silver
Flugelman Mazra Psychiatric Hospital, Doar Na Ashrat, Israel
Schizophr Res 52:265-73. 2001..We compared performance on tests of perception of facial emotions with that in other cognitive areas...
Working memory deficit as a core neuropsychological dysfunction in schizophreniaHenry Silver
Brain Behavior Laaboratory, Sha ar Menashe Mental Health Center, Hadera, Israel
Am J Psychiatry 160:1809-16. 2003..This study tested the hypothesis that impaired working memory is a core deficit underlying multiple neuropsychological deficits in schizophrenia patients...
Perception of happy and sad facial expressions in chronic schizophrenia: evidence for two evaluative systemsHenry Silver
Flugelman Mazra Psychiatric Hospital, Doar Na Ashrat, Israel
Schizophr Res 55:171-7. 2002..Persons suffering from schizophrenia have impaired perception of emotional expressions, but it is not clear whether this is part of a generalized deficit in cognitive function...
Fluvoxamine as an adjunctive agent in schizophreniaH Silver
Sha ar Menashe Mental Health Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
CNS Drug Rev 7:283-304. 2001..An important goal of future studies will be to define which patient groups can benefit from combined treatment...
Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophreniaHenry Silver
Sha ar Menashe Mental Health Center, Israel Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
Int Clin Psychopharmacol 18:305-13. 2003..Combination with clozapine may require particular caution because of potential toxicity if serum clozapine levels rise steeply. SSRI augmentation may be a useful addition to the treatment of schizophrenia...
Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled studyH Silver
Clinical Research Unit, Flugelman Mazra Psychiatric Hospital, Doar Na Ashrat Acco, Israel
Int Clin Psychopharmacol 15:257-61. 2000..The combination was well tolerated. Fluvoxamine augmentation of antipsychotics is safe in chronic schizophrenic patients with mixed positive and negative symptoms and may ameliorate negative symptoms in such patients...
Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptomsHenry Silver
Brain Behavior Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer, Israel
Schizophr Bull 29:541-6. 2003..The findings support the view that fluvoxamine augmentation can improve primary negative symptoms in chronic schizophrenia patients...
The onset and time course of response of negative symptoms to add-on fluvoxamine treatmentHenry Silver
Sha ar Menashe Mental Health Center, Hadera Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
Int Clin Psychopharmacol 18:87-92. 2003..Many symptoms, including those generally agreed to be core features of the illness such as alogia, improved within 2-3 weeks of treatment initiation...
Negative attitude towards medication is associated with working memory impairment in schizophrenia patientsCraig Goodman
Brain Behavior Laboratory, Sha'ar Menashe Mental Health Center, Hefer, Israel
Int Clin Psychopharmacol 20:93-6. 2005..Our findings support an association between negative attitudes towards medication and poor cognitive performance, particularly of working memory...
Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patientsMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
J Psychiatr Res 37:549-56. 2003....
Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatmentY Chertkow
Molecular Neuropsychiatry Unit, Shaar Menashe Brain Behavior Laboratory, Shaar Menashe MHC and Technion Faculty of Medicine, Haifa, Israel
J Neural Transm 114:1443-54. 2007..The possibility that these may be relevant to the mechanism underlying the clinical effectiveness of augmentation treatment warrant further study...
Anhedonia and schizophrenia: how much is in the eye of the beholder?Henry Silver
Flugelman Mazra Psychiatric Hospital, Doar Na Ashrat, Israel
Compr Psychiatry 43:65-8. 2002..Many schizophrenic patients may have a greater capacity to experience pleasure than is apparent to the people around them...
Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamineYael Chertkow
Molecular Neuropsychiatry Unit, Shaar Menashe Brain Behavior Laboratory, Shaar Menashe MHC, and Technion Faculty of Medicine, Haifa, Israel
Prog Neuropsychopharmacol Biol Psychiatry 31:1356-62. 2007..Our findings suggest that gene expression changes in PMC may be useful in investigating the mechanism of drug action in schizophrenia...
The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortexYael Chertkow
Molecular Neuropsychiatry Unit, Shaar Menashe MHC, and Technion - Faculty of Medicine, Haifa, Israel
Int J Neuropsychopharmacol 9:287-96. 2006..The present findings support the existence of a unique mechanism for SSRI-antipsychotic combination, different from that of the individual drugs and suggest that it may involve modification of the gamma aminobutyric acid (GABA) system...
Insight into illness in schizophreniaCraig Goodman
Brain Behavior Laboratory, Sha'ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
Compr Psychiatry 46:284-90. 2005..Our findings support an association between poor insight and cognitive impairment in patients with chronic schizophrenia but suggest that the relationship may not specifically involve frontal lobe dysfunction...
Lymphocytes, autoantibodies and psychosis--coincidence versus etiological factor: an updateM Schwartz
Dept of Neurology, Bnai Zion Medical Center, Haifa, Israel
Isr J Psychiatry Relat Sci 37:32-6. 2000..These results suggest that schizophrenia may result from an immunologic disorder, which is mediated mainly (but probably not only) by lymphocyte dysfunction...
Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophreniaYael Chertkow
Eve Topf Center of Excellence for Neurodegenerative Diseases Research, Department of Pharmacology, Technion Faculty of Medicine, Haifa, Israel
J Neural Transm 116:1529-41. 2009..While as yet limited in scope, the evidence suggests definable molecular targets which may be implicated in drug development based on SSRI-antipsychotic synergistic actions...
The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic studyMichael Ritsner
Institute for Psychiatric Studies, Sha ar Menashe Mental Health Center, Hadera, Israel
Eur Neuropsychopharmacol 12:31-8. 2002..Patient's subjective response to these events rather than their number is more predictive of QOL...
Schizophrenic patients who smoke have a faster finger tapping rate than non-smokersHenry Silver
Flugelman Mazra Psychiatric Hospital, Doar Na Ashrat, Israel
Eur Neuropsychopharmacol 12:141-4. 2002..Nicotine can improve central processing in medicated schizophrenia patients and this may constitute part of the incentive for smoking...
Animal-assisted therapy ameliorates anhedonia in schizophrenia patients. A controlled pilot studyInbar Nathans-Barel
Brain Behavior Laboratory, Sha'ar Menashe Mental Health Center, Mobile Post Hefer, Haifa, Israel
Psychother Psychosom 74:31-5. 2005..They also showed an improvement in the use of leisure time and a trend towards improvement in motivation. CONCLUSION: AAT may contribute to the psychosocial rehabilitation and quality of life of chronic schizophrenia patients...
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effectsChristoph Hiemke
Department of Psychiatry, University of Mainz, Germany
J Clin Psychopharmacol 22:502-6. 2002....
Selective serotonin reuptake inhibitor add-on therapy for the negative symptoms of schizophreniaHenry Silver
J Clin Psychiatry 69:163-4. 2008
Neuropsychological correlates of homocysteine levels in euthymic bipolar patientsYamima Osher
Beer Sheva Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
J Affect Disord 105:229-33. 2008..The current study was designed to extend this finding by examining the relationship between neuropsychological functioning and homocysteine levels in euthymic bipolar patients...
